Here are the Form 4 insider transactions from Oramed Pharmaceuticals Inc. (ORMP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ORMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORMP filings page.
Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay sold 20,000 common shares on October 1, 2026, at a weighted average price of $4.51 per share. The shares were sold in multiple transactions at prices ranging from $4.440 to $4.650. The sale was made under a Rule 10b5-1 trading plan adopted March 30, 2026. Following the sale, 861,076 shares were directly held.
Oramed Pharmaceuticals Inc. COO & CBO Joshua Hexter sold 30,000 common shares on October 1, 2026, at a weighted average price of $4.511 per share. The sales were made under a Rule 10b5-1 trading plan adopted March 30, 2026. He directly held 1,328,130 shares after the sale.
Oramed Pharmaceuticals Inc. President and CEO Nadav Kidron reported that the issuer canceled all of his outstanding stock options on September 24, 2026, in an option exchange program. He received a fully vested restricted stock award of 349,497 shares, valued at $4.75 per share—the closing price on September 22, 2026—and equal to the aggregate Black-Scholes value of the canceled options. The canceled options covered 196,500, 190,000, 49,000, 97,000, 150,000, and 107,000 shares, with exercise prices of $3.16, $4.80, $7.77, $8.14, $10.40, and $13.89, respectively. Separately, the issuer granted him 368,765 restricted shares under its Amended and Restated 2019 Stock Incentive Plan. A separate holding entry lists 126,000 common shares held indirectly by a wholly owned corporation.
ORAMED PHARMACEUTICALS INC. COO & CBO Joshua Hexter reported that on September 24, 2026, the company canceled all his outstanding stock options under an option exchange program. In exchange, he received a 75,455-share restricted stock award, fully vested upon grant and valued at $4.75 per share, equal to the canceled options’ aggregate Black-Scholes value. The company also granted him a separate 209,291-share restricted stock award; vesting is subject to continued service.
ORAMED Pharmaceuticals (ORMP) canceled all outstanding stock options held by Chief Scientific Officer and director Miriam Kidron on September 24, 2026, under an option exchange program. In exchange, she received a 208,125-share restricted stock award that fully vested upon grant, valued at $4.75 per share, the September 22, 2026 closing price; the award equaled the canceled options’ aggregate Black-Scholes value. She also received a separate 209,291-share award under the Amended and Restated 2019 Stock Incentive Plan: 40% vested on the grant date, with the remaining 60% vesting in eight substantially equal quarterly installments over 24 months, subject to continued service. Unvested shares are subject to forfeiture. No Rule 10b5-1 plan is reported.
ORAMED PHARMACEUTICALS INC. Chief Financial Officer Gabay Avraham acquired a restricted stock award of 209,291 shares on September 24, 2026, under the Amended and Restated 2019 Stock Incentive Plan. Forty percent vests on the grant date; the remaining 60% vests in eight substantially equal quarterly installments over the 24-month period following the grant, subject to continued service. Unvested shares are subject to forfeiture under the award agreement and Plan. His direct holdings following the award were 881,076 shares.
Oramed Pharmaceuticals COO & CBO Joshua Hexter reported an option exercise and share sale in the company’s stock. On July 2, 2026, he exercised 50,000 stock options at $3.69 per share, receiving an equal number of common shares. On July 1, 2026, he sold 137,000 common shares at a weighted average price of $4.463 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 1,073,384 common shares and 50,000 stock options that remain outstanding.
ORAMED PHARMACEUTICALS INC. Chief Financial Officer Avraham Gabay reported an open-market sale of 73,360 shares of common stock on July 1, 2026 at a weighted average price of $4.5085 per share. The transaction was executed as a planned sale under a Rule 10b5-1 trading plan adopted on March 30, 2026, indicating it was pre-arranged rather than timed discretionarily. Following this sale, Gabay directly holds 671,785 shares, showing he retains a substantial equity position in the company.
ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a routine tax-related share disposition. On March 30, 2026, 44,818 shares of common stock were used to satisfy tax withholding obligations from the vesting of Restricted Stock Units at $3.31 per share. These shares were not sold in the open market but withheld to cover taxes. Following this, Kidron directly holds 3,422,243 common shares and indirectly holds 126,000 common shares through a wholly-owned corporation.
ORAMED PHARMACEUTICALS INC. Chief Scientific Officer Miriam Kidron reported a tax-related share disposition tied to equity compensation. A total of 435,084 shares of common stock were used to satisfy tax withholding obligations from the vesting and settlement of Restricted Stock Units. These shares were valued at $3.31 per share, based on the closing price immediately before the vesting date. Following this tax-withholding disposition, Kidron directly holds 1,133,138 shares of Oramed common stock.
ORAMED PHARMACEUTICALS INC. reported that Chief Scientific Officer Miriam Kidron received a grant of 119,558 restricted stock units (RSUs) of common stock. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, providing staged equity-based compensation over two years.
Each RSU represents the right to receive one share of common stock with a par value of $0.012 per share. Following this award, Kidron’s reported direct holdings increased to 1,568,222 shares of common stock, indicating this is a sizable but compensation-related, non-cash acquisition rather than an open-market purchase.
KIDRON NADAV reported acquisition or exercise transactions in this Form 4 filing.
Oramed Pharmaceuticals reported that President and CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units (RSUs) of common stock at no cash cost. The award increases his direct holdings to 3,422,243 shares after the transaction.
The RSUs will vest in eight equal quarterly installments beginning April 1, 2026, aligning a portion of the CEO’s compensation with the company’s long-term performance. Each RSU represents the right to receive one share of Oramed common stock as it vests.
Hexter Joshua reported acquisition or exercise transactions in this Form 4 filing.
ORAMED PHARMACEUTICALS INC. reported that its COO & CBO, Joshua Hexter, received a grant of 95,889 shares of Common Stock in the form of Restricted Stock Units. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, with each RSU delivering one share upon vesting. Following this award, Hexter directly holds a total of 1,160,384 shares of the company’s common stock, reflecting a compensation-related equity grant rather than an open-market purchase.
Oramed Pharmaceuticals Chief Financial Officer Avraham Gabay received an equity grant of 95,889 Restricted Stock Units (RSUs). The RSUs vest in eight equal quarterly installments beginning on April 1, 2026, encouraging longer-term retention. Each RSU converts into one share of common stock when it vests, bringing his direct holdings to 745,145 shares after the award.
ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a bona fide charitable gift of 100,000 shares of Common Stock on March 12, 2026. The filing states this was a charitable donation, not a market transaction, and no value was received for the shares.
Following the donation, Kidron directly holds 3,255,238 shares of Oramed common stock. The footnote further explains that he is not affiliated with, and has no control over, the charitable donee, underscoring that this is a non-economic transfer rather than a sale in the open market.
Oramed Pharmaceuticals executive Joshua Hexter reported a share-based award vesting. On January 22, 2026, 19,000 performance stock units vested after Oramed’s common stock reached a specified price target. Each unit converted into one common share, giving Hexter 19,000 shares received for no cash consideration.
Following this conversion, Hexter directly holds 1,064,495 shares of Oramed common stock. The performance stock units were granted on December 31, 2025, and no derivative units of this grant remain outstanding after the vesting.
Oramed Pharmaceuticals (ORMP) director and Chief Scientific Officer Miriam Kidron reported the vesting of performance stock units (PSUs) into common shares. On January 22, 2026, 19,000 PSUs vested after Oramed’s common stock reached a specified price level.
Each PSU converted into one share of common stock, so Kidron received 19,000 shares of Oramed common stock for no cash consideration. Following this equity-based award, she directly beneficially owns 1,448,664 shares of Oramed common stock, reflecting her ongoing equity stake in the company.
Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay reported the vesting of 19,000 performance stock units into common shares. The PSUs were granted on December 31, 2025 and vested on January 22, 2026 after Oramed’s common stock reached a specified price per share.
Each PSU converted into one share of common stock, and the shares were received for no cash consideration. Following this transaction, Gabay directly beneficially owns 649,256 shares of Oramed common stock.
Oramed Pharmaceuticals Inc. insider filing: President and CEO Nadav Kidron reported the vesting of performance stock units tied to Oramed’s share price. On January 22, 2026, 109,000 PSUs converted into 109,000 shares of common stock for no cash consideration.
Each PSU gave the right to receive one share when specific performance criteria were met. Following this vesting, Kidron directly owns 3,355,238 shares of Oramed common stock.
Oramed Pharmaceuticals director and Chief Scientific Officer Miriam Kidron reported a charitable donation of company stock. On 01/14/2026, she gifted 86,166 shares of Oramed Pharmaceuticals Inc. common stock in a transaction coded "G," which is designated for gifts. The filing states this was a charitable donation, not a market trade, so no price was reported and no value was received for the shares.
After the donation, Kidron beneficially owned 1,343,498 shares of Oramed common stock in direct ownership form. The footnote adds that she is not affiliated with, and has no control over, the recipient organization.